Somewhat Favorable News Coverage Somewhat Unlikely to Impact Viking Therapeutics (VKTX) Stock Price
News articles about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8419874161658 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Viking Therapeutics (NASDAQ VKTX) traded down $0.09 on Friday, reaching $4.74. The company’s stock had a trading volume of 678,190 shares, compared to its average volume of 666,919. The company has a market cap of $173.00, a price-to-earnings ratio of -5.64 and a beta of 1.88. Viking Therapeutics has a 1 year low of $0.88 and a 1 year high of $5.43.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). research analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-viking-therapeutics-vktx-stock-price/1806086.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.